<DOC>
	<DOCNO>NCT01805297</DOCNO>
	<brief_summary>To evaluate ocular systemic safety intravitreal aflibercept injection patient undergoing Pars Plana Vitrectomy Proliferative Diabetic Retinopathy .</brief_summary>
	<brief_title>Aflibercept Injection Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>Patients need Pars Plana Vitrectomy surgery , agree participate study receive injection 2.0mg aflibercept 4 6 day Vitrectomy surgery . Half patient randomize receive another injection 2.0mg aflibercept immediately surgery . Postoperative patient visit study 1 day , week 1 , 4 , 16 24 , time deem necessary Investigator .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Diagnosed proliferative diabetic retinopathy ( PDR ) require par plana vitrectomy ( PPV ) Best correct visual acuity study eye 20/40 light perception ( LP ) use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart Pregnancy ( positive urine pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , intrauterine device ( IUD ) , contraceptive hormone implant patch . Participation study investigational drug device within past 30 day prior enrol study For previously treat subject Prior treatment antivascular endothelial growth factor ( antiVEGF ) therapy study eye within 28 day Screening Prior treatment triamcinolone study eye within 6 month Screening . Prior treatment dexamethasone study eye within 30 day Screening Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Baseline History vitrectomy surgery , submacular surgery , surgical intervention PDR study eye Active intraocular inflammation ( grade trace ) study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Uncontrolled glaucoma study eye ( defined intraocular pressure ( IOP ) â‰¥ 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 6 month study enrollment . History allergy fluorescein , indocyanine green ( ICG ) iodine , amenable treatment Presence macular traction Uncontrolled hypertension ( e.g. , 120/200 mmHg ) prior surgery ( PPV ) Concomitant use systemic antiVEGF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
</DOC>